MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it had initiated a

Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19 Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant Adverse events reported were similar to placebo, with 12.4% of subjects experiencing commonly known side

MALVERN, PA , June 22, 2021 - Ocugen, Inc. (NASDAQ: OCGN) is reminding stockholders about the adjournment of its 2021 Annual Meeting to a new date and time. The Annual Meeting was convened as initially scheduled on June 11, 2021.  As there was not a sufficient number of shares represented in person

MALVERN, Pa., June 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Ken Inchausti has

MALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the

Jubilant HollisterStier to manufacture COVAXIN™ in the US MALVERN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be

Company intends to work with the FDA towards filing a Biologics License Application (BLA) in the US Company to engage with Health Canada to seek authorization under Interim Order for use in Canada MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.

Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN™ in Canada, in addition to its existing US rights MALVERN, Pa. and HYDERABAD, India, June 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering,